We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current EGRX market cap is 10.39M. The company's latest EPS is USD 2.7444 and P/E is 0.78.
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 213.31M | 195.89M | 187.8M | 171.55M | 316.61M |
| Operating Income | 38.56M | 21.82M | 32.95M | 2.77M | 80.96M |
| Net Income | 31.9M | 14.31M | 11.99M | -8.63M | 35.64M |
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 238.6M | 254.55M | 253.19M | 253.73M | 406.16M |
| Total Liabilities | 77.84M | 75.38M | 67.18M | 77.28M | 172.6M |
| Total Equity | 160.76M | 179.17M | 186.01M | 176.45M | 233.56M |
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 52.38M | 55.99M | 49.5M | 28.22M | 50.7M |
| Investing | -133k | -777k | -18.25M | -5.32M | -86.83M |
| Financing | -88.12M | -24.23M | -37.87M | -28.39M | 13.79M |
| Market Cap | 10.39M |
| Price to Earnings Ratio | 0.78 |
| Price to Sales Ratio | 0.09 |
| Price to Cash Ratio | 0.5 |
| Price to Book Ratio | 0.12 |
| Dividend Yield | - |
| Shares Outstanding | 12.99M |
| Average Volume (1 week) | 1.84k |
| Average Volume (1 Month) | 8.89k |
| 52 Week Change | -59.39% |
| 52 Week High | 2.40 |
| 52 Week Low | 0.0025 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Eagle Pharmaceuticals Inc (CE) |
| Address |
corporation trust center wilmington, delaware 19801 |
| Website | https://www.eagleus.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
